A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants
A Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 Following Single Ascending Dose Administration to Healthy Participants
Sponsor: AstraZeneca
This PHASE1 trial investigates Healthy Participants and Pharmacokinetics and is currently completed. AstraZeneca leads this study, which shows 13 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Nov 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE1
▶ Show 8 earlier versions
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE1
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1
First recorded
Dec 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .